DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Shares of Bioventus (BVS) have surged 73% in the past three months, significantly outperforming the industry’s 1.3% growth. The stock has outperformed the sector and the S&P 500 during the same period. BVS' shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis uptick in stock price was triggered by the company’s encouraging sales performance across its business segments, especially the Pain Treatments ...

The stock price of Bioventus (BVS) has more than doubled in the past six months. This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year. In the past six months, BVS stock significantly outperformed the industry's 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages. BVS Stock Outperforms ...

Bioventus (BVS) is a Zacks Rank #1 (Strong Buy) that has a C for Value and an A for Growth. This company makes drugs that help people heal quickly and safely. They target osteoarthritis, surgical and non surgical bones healing. Let's explore more about this company in this Bull of The Day article. Description Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculos ...

Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

Exhibit 99.1 Bioventus Reports Second Quarter Financial Results • Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% • Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps • Cash from Operations of $15.2 million Increased 40.5% • Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities DURHAM, NC – August 6, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, ...

Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps Cash from Operations of $15.2 million Increased 40.5% Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and si ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint that was filed against Bioventus on January 12, 2023 with a Class Period pursuant to the February 11, 2021 IPO. Our investigation concerns whether the board of directors of Bioventus have breached their fiduciary duties to the company. Bioventu ...